Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage

University of Leipzig

Status: Unknown

Conditions: Atrial Fibrillation; Stroke Prevention; Left Atrial Appendage

Treatments: Device: WATCHMAN LAA system (Percutaneous left atrial appendage closure)

Study type: Interventional

Funder types: Other

Identifiers

NCT01522911

LAA-1

Details and patient eligibility

About

To date there are no data suggesting substantial effects of hormonal interaction after percutaneous closure of the left atrial appendage (LAA). Our hypothesis is that by excluding the LAA from blood flow physiologic stimuli for ANP and BNP produce may be impaired and consecutive release of the hormones may be reduced. Here, we present our experience of ANP and BNP secretion in the early postprocedural period after transcatheter closure of the LAA.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non-valvular atrial fibrillation
• increased risk for thromboembolic complications (a minimum CHADS2Score of at least 2)

Exclusion criteria

• Valvular-atrial fibrillation
• Low risk for thromboembolic complications CHADS-2-Score < 2

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

atrial and brain natriuretic peptide

Other group

Description:

Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure

Treatment:

Device: WATCHMAN LAA system (Percutaneous left atrial appendage closure)